CRSP earnings: next report 2026-08-03, real EPS beat/miss history, analyst consensus Buy, P/E -7.59. Updated 2026-07-23.
CRISPR Therapeutics (CRSP) Research Hub
CRISPR Therapeutics (CRSP) trades on NASDAQ, CH in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 51.72 USD (-3.24%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -7.59, market cap 4.54B. This hub links to the full technical, earnings and options research available for CRSP.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, CH |
| Last close | 51.72 USD (-3.24%) |
| 52-week range | 45.89 USD – 63.45 USD |
| Trend regime | Range |
| 14-day RSI | 44.8 (Bearish) |
| Trailing P/E | -7.59 |
| Market cap | 4.54B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-03 |
Available research for CRSP
Covered Call on CRSP: how it works, illustrative setup around the real 51.72 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on CRSP: how it works, illustrative setup around the real 51.72 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on CRSP: how it works, illustrative setup around the real 51.72 USD price, max profit/loss, breakeven and when to use it. Educational.
CRSP technical analysis: range, last 51.72 USD, RSI 44.8, 52w range 45.89 USD–63.45 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is CRSP in?
CRISPR Therapeutics (CRSP) is classified under Healthcare (Biotechnology), listed on NASDAQ, CH.
Is CRSP in an uptrend or downtrend?
As of 2026-09-11, CRSP is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is CRSP's trailing P/E ratio?
CRSP's trailing P/E is -7.59, with a market cap of 4.54B. See the earnings research page for full valuation detail.
When does CRSP next report earnings?
CRSP is next scheduled to report earnings on 2026-08-03, with a consensus EPS estimate of -1.19931 USD.